Jpmorgan Chase & CO Morphic Holding, Inc. Transaction History

Jpmorgan Chase & CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$26.12 - $34.07 $65,117 - $84,936	-2,493 Reduced 6.11%	38,288 $1.3 Million
Q1 2024 May 10, 2024	SELL	$26.64 - $40.31 $521,238 - $788,705	-19,566 Reduced 32.42%	40,781 $1.44 Million
Q4 2023 Feb 12, 2024	BUY	$19.95 - $31.0 $120,717 - $187,581	6,051 Added 11.14%	60,347 $1.74 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $23,740 - $66,134	1,113 Added 2.09%	54,296 $1.24 Million
Q2 2023 Aug 11, 2023	BUY	$34.33 - $62.11 $638,503 - $1.16 Million	18,599 Added 53.78%	53,183 $3.05 Million
Q1 2023 May 18, 2023	BUY	$26.01 - $48.69 $890,920 - $1.67 Million	34,253 Added 10348.34%	34,584 $1.3 Million
Q1 2023 May 11, 2023	SELL	$26.01 - $48.69 $723,598 - $1.35 Million	-27,820 Reduced 98.82%	331 $12,000
Q4 2022 Feb 13, 2023	BUY	$24.14 - $30.37 $38,961 - $49,017	1,614 Added 6.08%	28,151 $753,000
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $46,927 - $70,444	2,111 Added 8.64%	26,537 $751,000
Q2 2022 Aug 11, 2022	BUY	$19.74 - $43.01 $80,499 - $175,394	4,078 Added 20.04%	24,426 $531,000
Q1 2022 May 11, 2022	BUY	$36.25 - $52.02 $138,656 - $198,976	3,825 Added 23.15%	20,348 $816,000
Q4 2021 Feb 10, 2022	SELL	$43.27 - $65.72 $499,076 - $758,014	-11,534 Reduced 41.11%	16,523 $783,000
Q3 2021 Nov 12, 2021	BUY	$53.61 - $67.5 $1.5 Million - $1.89 Million	28,057 New	28,057 $1.59 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.